Johnson and Johnson’s Janssen business unit has released its 2017 Janssen U.S. Transparency Report, which offers a look inside the pharmaceutical company’s commercial activity.
A free download of Janssen’s report can be found here.
Janssen in its report says the list price for its pharmaceutical products posted 8.1 percent growth last year, though net prices saw a 4.6 percent dip.
The company also put up $15 billion for rebates and discounts, which cut 42 percent from its list prices.
Drug Channels in a report published Tuesday offers a breakdown of some key takeaways from the report.